| Name | Title | Contact Details |
|---|
GuideWell Mutual Holding Corporation is a not-for-profit mutual holding company that is the parent to a family of forward-thinking companies focused on transforming health care.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Parker Health is a Mexican American founded company; a powerful global agent of change, driven by minority-led leadership, diversity, and innovation. Our mission is resolute: to advance healthcare and technology into the next century by simplifying complexities and realizing the potential of digital health innovation. At the core of our approach is the groundbreaking Parker EHR – a revolutionary Electronic Health Records Management System™ that redefines interoperability, accessibility, and compliance. This innovation empowers patients, healthcare providers, systems, governments, researchers, and payors through a seamless cloud-based architecture that harmonizes patient-centric data, diagnostics, outcomes, care protocols, practitioner engagement, and more. Headquartered in Washington, DC, Parker Health signifies a global catalyst for transformation, rewriting the rules of healthcare through innovative solutions that forge a brighter future.
AIM Specialty Health® provides clinical solutions that drive appropriate, safe, and affordable care. Serving more than 50 million members across 50 states, D.C. and US territories, AIM promotes optimal care through use of evidence-based clinical guidelines and real-time decision support for both providers and their patients. The AIM platform delivers significant cost of care savings across an expanding set of clinical domains including radiology, cardiology, oncology, specialty drugs, sleep medicine, musculoskeletal, pain management, and genetic testing. AIM is a wholly-owned subsidiary of Anthem, Inc. (ANTM).
VNA of Rhode Island is a Warwick, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.